In response to antibiotics, a gene regulation network found in the bacterium Acinetobacter baumannii acts to boost both virulence and antibiotic resistance. Edward Geisinger of Tufts University School of Medicine and colleagues present new insights into this system in a study published in PLOS Pathogens.
Some examples of the persistence of incompletely resolved issues in asthma management are: 1) misdiagnosis -- with the related complex consequences --, especially in children population and, 2) poor control of the disease. Also related factors as suboptimal medical management , poor education and health literacy of patients, poor adherence and elevated costs for patients and healthcare systems are some other factors that need urgent implementation.
Using an original mathematical and statistical analysis method, a team of scientists from the Institut Pasteur partnered with researchers from the United States and Thailand to analyze a Thai cohort in order to help identify individuals at risk of infection. By modeling changes in antibody levels after successive infections with the different dengue serotypes, the scientists were able to establish the profile of these individuals. The findings will be published online in Nature on May 23, 2018 (AOP).
An overwhelming majority of Americans (95 percent) think infectious and emerging diseases facing other countries will pose a 'major' or 'minor' threat to the US in the next few years, but more than half (61 percent) say they are confident the federal government can prevent a major infectious disease outbreak in the US, according to a new national public opinion survey commissioned by Research!America and the American Society for Microbiology.
A nanoparticle vaccine developed by MIT researchers could help eradicate polio worldwide. The vaccine, which delivers multiple doses in just one injection, could make it easier to immunize children in remote regions of Pakistan and other countries where the disease is still found.
A major route toward creating effective vaccines against dengue virus and Zika involves the E protein that covers the surface of each viral particle. But creating such a vaccine has proven difficult for a number of reasons. Now UNC School of Medicine researchers have delineated the details of one major barrier to a promising vaccine. It's something we all have -- a natural body temperature of about 98.6 degrees.
A new study shows that a kind of E. coli most associated with 'travelers' diarrhea' and children in underdeveloped areas of the world causes more severe disease in people with blood type A. The bacteria release a protein that latches onto intestinal cells in people with blood type A, but not blood type O or B, according to a study led by researchers at Washington University School of Medicine in St. Louis.
New research in mice suggests that chronic infection with intestinal worms indirectly reduces the number of cells in lymph nodes near the skin, inhibiting the immune system's response to the Bacille Calmette-Guerin (BCG) vaccine for tuberculosis. Xiaogang Feng of Karolinska Institutet in Stockholm, Sweden, and colleagues present these findings in PLOS Pathogens.
Research conducted in vitro shows two human antibodies made in response to vaccination against one hemorrhagic fever virus can disarm a related virus, for which there is currently no vaccine. The proof-of-principle finding identifies a common molecular chink in the two viruses' armor that renders both vulnerable to the same antibodies. The results set the stage for a single vaccine and other antibody-based treatments that work against multiple viral 'cousins' despite key differences in their genetic makeup.
Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease. However, this perspective has recently been challenged as scientists have taken a lesson from plant biologists about an ancient strategy involving the ability to 'tolerate' rather than 'resist' infection to maintain health. This concept, referred to as 'disease tolerance,' provides an opportunity to develop new strategies that mitigate the consequences of infection.